Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

AMLM26/T5 INTERCEPT : AMLM26/T5- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - MBG453 OR MBG453 and Azacitidine

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAcute Myeloid Leukaemia

Trial Overview Read MoreRead more

This phase I/II study is evaluating the effective a new treatment (MBG453) alone, and in combination with another treatment (azacitadine), in people with progressive acute myeloid leukaemia.
 

This trial is treating patients with acute myeloid leukaemia.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

AMLM26/T5- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - MBG453 OR MBG453 and Azacitidine

Cooperative Group

Australasian Leukaemia and Lymphoma Group (ALLG)

Summary

This is a sub-porotocl for the multi-arm INTERCEPT trial (master protocol can be found by searching ACTRN12621000439842). Eligible participants will be randomly allocated to one of two treatment arms. In Treatment Arm A, participants will receive MBG453 (via intravenous infusion) at a dose of 800mg on Day 1 of a 28 day cycle. In Treatment Arm B, participants will receive azacitidine (subcutaneously or intravenously) at a dose of 75mg/m2 on days 1-8, and MGB453 (intravenously) at a dose of 800mg on day 8. Azacitidine will be given from days 1-7 or using the 5-2-2 schedule with MGB453 on day 8 out of a 28-day cycle. Both treatment arms will be given for 12 cycles.

Recruiting Hospitals Read MoreRead more

Barwon Health, University Hospital Geelong
Geelong
Haematology Team
HaematologyTrials@barwonhealth.org.au

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next